Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Novacyt ( (FR:ALNOV) ) has issued an announcement.
Novacyt S.A. has announced the appointment of Singer Capital Markets as its joint corporate broker, effective immediately. This strategic move is expected to enhance Novacyt’s market presence and strengthen its financial advisory team, working alongside SP Angel, the company’s existing joint corporate broker. The appointment reflects Novacyt’s commitment to bolstering its corporate governance and investor relations, potentially impacting its operations and industry positioning positively.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. The company develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver seamless end-to-end solutions across sectors including human health, animal health, and environmental. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, offering products and services in areas such as reproductive health, precision medicine, infectious diseases, DNA sample preparation, and qPCR assays. Headquartered in Le Vésinet, France, with offices in the UK, Singapore, the US, and Canada, Novacyt is listed on the London Stock Exchange’s AIM market and the Paris Stock Exchange Euronext Growth.
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.